Lp-PLA2 Activity – New York Clients Only

Cleveland HeartLab Inflammation, L, Test

NEW YORK DOH APPROVED: YES
CPT Code: 83698
Order Code: C570
ABN Requirement:  No
Synonyms: Lipoprotein-associated Phospholipase A2; Lp-PLA2; Lp-PLA2 Activity Assay
Specimen: Serum or EDTA Plasma
Volume: 1.0 mL
Minimum Volume: 0.5 mL
Container:

Serum: Gel-barrier tube (SST, Tiger Top) preferred

Plasma: EDTA (Lavender Top tube)

Collection:

Serum:

  1. Collect and label sample according to standard protocols.
  2. Gently invert tube 5 times immediately after draw. DO NOT SHAKE.
  3. Allow blood to clot 30 minutes.
  4. Centrifuge for 10 minutes.

EDTA Plasma:

  1. Draw and gently invert 8 to 10 times.
  2. Centrifuge for 10 minutes.
  3. Pre-squeeze transfer pipet bulb and draw off approximately 2/3 of the upper plasma layer.
    Note: This ensures that the buffy coat and red cells remain undisturbed.
  4. Aliquot plasma into labeled transport tube labeled as “EDTA plasma” and cap tightly. Discard original tube.
  5. Store transport tube refrigerated at 2-8°C until ready to ship.

Transport: Store serum or EDTA plasma at 2°C to 8°C after collection and ship the same day per packaging instructions included with the provided shipping box.

Stability:

Ambient (15-25°C): 21 days
Refrigerated (2-8°C): 180 days
Frozen (-20°C): 180 days

Causes for Rejection:  Specimens other than serum or EDTA plasma; samples not processed properly; samples older than stability limits

Methodology: Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)

Turn Around Time: 3 to 5 days

Relative Risk Ranges:

Sex Low Risk
nmol/min/mL
High Risk
nmol/min/mL
Male/Female <75 ≥75

Clinical Significance: Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low-density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.